


PHARMACEUTICAL 2021



SELECTA BIOSCIENCES INC Rank 233 of 409





PHARMACEUTICAL 2021



SELECTA BIOSCIENCES INC Rank 233 of 409

The relative strengths and weaknesses of SELECTA BIOSCIENCES INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of SELECTA BIOSCIENCES INC compared to the market average is the variable Selling, General and Administrative Expense, increasing the Economic Capital Ratio by 38% points. The greatest weakness of SELECTA BIOSCIENCES INC is the variable Research and Development, reducing the Economic Capital Ratio by 28% points.

The company's Economic Capital Ratio, given in the ranking table, is -172%, being 183% points above the market average of -355%.

Input Variable	Value in 1000 USD
Assets, Current	151,343
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	81,547
Liabilities, Non-Current	48,393
Other Assets	12,697
Other Compr. Net Income	-40
Other Expenses	11,999
Other Liabilities	53,501
Other Net Income	-56
Property and Equipment	1,395
Research and Development	54,505
Revenues	16,597
Selling, General and Administrative Expense	18,913

Output Variable	Value in 1000 USD
Assets	165,435
Liabilities	183,441
Expenses	85,417
Stockholders Equity	-18,006
Net Income	-68,876
Comprehensive Net Income	-68,896
Economic Capital Ratio	-172%